|
|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
4
|
Morphine
|
Cataract
|
1110410
|
375545
|
Morphine & Cataract
|
## Chronograph ##

## Basic demographioc table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
359
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
200
|
56
|
Sex
|
gender = FEMALE
|
570
|
57
|
Sex
|
gender = FEMALE
|
552
|
55
|
Sex
|
gender = FEMALE
|
575
|
58
|
|
|
gender = MALE
|
159
|
44
|
|
gender = MALE
|
430
|
43
|
|
gender = MALE
|
448
|
45
|
|
gender = MALE
|
425
|
42
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
3
|
1
|
|
(20,30]
|
6
|
1
|
|
(20,30]
|
6
|
1
|
|
(20,30]
|
5
|
0
|
|
|
(30,40]
|
10
|
3
|
|
(30,40]
|
21
|
2
|
|
(30,40]
|
9
|
1
|
|
(30,40]
|
18
|
2
|
|
|
(40,50]
|
8
|
2
|
|
(40,50]
|
50
|
5
|
|
(40,50]
|
33
|
3
|
|
(40,50]
|
39
|
4
|
|
|
(50,60]
|
25
|
7
|
|
(50,60]
|
80
|
8
|
|
(50,60]
|
52
|
5
|
|
(50,60]
|
62
|
6
|
|
|
(60,70]
|
90
|
25
|
|
(60,70]
|
216
|
22
|
|
(60,70]
|
251
|
25
|
|
(60,70]
|
242
|
24
|
|
|
(70,80]
|
122
|
34
|
|
(70,80]
|
347
|
35
|
|
(70,80]
|
354
|
35
|
|
(70,80]
|
356
|
36
|
|
|
(80,90]
|
81
|
23
|
|
(80,90]
|
226
|
23
|
|
(80,90]
|
254
|
25
|
|
(80,90]
|
227
|
23
|
|
|
(90,110]
|
20
|
6
|
|
(90,110]
|
54
|
5
|
|
(90,110]
|
41
|
4
|
|
(90,110]
|
51
|
5
|
|
|
Median
|
74
|
IQR=(68, 81)
|
|
Median
|
74
|
IQR=(67, 82)
|
|
Median
|
75
|
IQR=(68, 82)
|
|
Median
|
74
|
IQR=(68, 81)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 359)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 359)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
1.4
|
1.6
|
0.02
|
|
25 - 29
|
0.8
|
0.5
|
-0.04
|
Visual system disorder
|
50.7
|
34.1
|
-0.34
|
|
30 - 34
|
0.3
|
0.5
|
0.04
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.9
|
1.4
|
-0.04
|
Atrial fibrillation
|
46.0
|
30.4
|
-0.32
|
|
40 - 44
|
0.6
|
1.4
|
0.09
|
Cerebrovascular disease
|
14.8
|
12.2
|
-0.08
|
|
45 - 49
|
1.7
|
2.9
|
0.08
|
Coronary arteriosclerosis
|
47.4
|
37.6
|
-0.20
|
|
50 - 54
|
2.5
|
3.5
|
0.06
|
Heart disease
|
82.5
|
67.1
|
-0.36
|
|
55 - 59
|
3.3
|
4.9
|
0.08
|
Heart failure
|
37.6
|
28.7
|
-0.19
|
|
60 - 64
|
5.3
|
3.8
|
-0.07
|
Ischemic heart disease
|
20.6
|
16.9
|
-0.10
|
|
65 - 69
|
14.8
|
13.4
|
-0.04
|
Peripheral vascular disease
|
42.6
|
35.4
|
-0.15
|
|
70 - 74
|
19.8
|
18.2
|
-0.04
|
Pulmonary embolism
|
5.6
|
2.8
|
-0.14
|
|
75 - 79
|
17.8
|
17.1
|
-0.02
|
Venous thrombosis
|
10.9
|
6.6
|
-0.15
|
|
80 - 84
|
14.5
|
14.6
|
0.00
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
9.7
|
10.8
|
0.03
|
Hematologic neoplasm
|
14.8
|
11.5
|
-0.10
|
|
90 - 94
|
4.5
|
4.2
|
-0.01
|
Malignant lymphoma
|
8.4
|
5.6
|
-0.11
|
|
95 - 99
|
1.9
|
2.3
|
0.02
|
Malignant neoplasm of anorectum
|
1.1
|
1.3
|
0.02
|
|
100 - 104
|
0.6
|
0.5
|
-0.01
|
Malignant neoplastic disease
|
42.6
|
32.2
|
-0.22
|
|
Gender: female
|
55.7
|
57.0
|
0.03
|
Malignant tumor of breast
|
6.7
|
4.5
|
-0.10
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
7.8
|
3.8
|
-0.17
|
|
Acute respiratory disease
|
32.3
|
22.0
|
-0.23
|
Malignant tumor of lung
|
5.3
|
4.5
|
-0.04
|
|
Attention deficit hyperactivity disorder
|
0.8
|
0.6
|
-0.03
|
Malignant tumor of urinary bladder
|
5.8
|
2.4
|
-0.17
|
|
Chronic liver disease
|
4.2
|
4.0
|
-0.01
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
15.9
|
10.6
|
-0.16
|
Agents acting on the renin-angiotensin system
|
59.1
|
61.3
|
0.05
|
|
Crohn’s disease
|
0.8
|
1.1
|
0.03
|
Antibacterials for systemic use
|
51.5
|
50.7
|
-0.02
|
|
Dementia
|
15.9
|
15.4
|
-0.01
|
Antidepressants
|
51.5
|
56.0
|
0.09
|
|
Depressive disorder
|
14.5
|
15.7
|
0.03
|
Antiepileptics
|
31.2
|
36.1
|
0.10
|
|
Diabetes mellitus
|
71.3
|
61.0
|
-0.22
|
Antiinflammatory and antirheumatic products
|
37.3
|
34.4
|
-0.06
|
|
Gastroesophageal reflux disease
|
20.9
|
18.7
|
-0.06
|
Antineoplastic agents
|
16.7
|
14.1
|
-0.07
|
|
Gastrointestinal hemorrhage
|
12.3
|
7.3
|
-0.17
|
Antipsoriatics
|
0.3
|
0.6
|
0.05
|
|
Human immunodeficiency virus infection
|
0.8
|
0.6
|
-0.03
|
Antithrombotic agents
|
49.0
|
48.0
|
-0.02
|
|
Hyperlipidemia
|
38.4
|
28.8
|
-0.21
|
Beta blocking agents
|
54.9
|
56.8
|
0.04
|
|
Hypertensive disorder
|
6.4
|
5.5
|
-0.04
|
Calcium channel blockers
|
42.9
|
50.9
|
0.16
|
|
Lesion of liver
|
4.7
|
4.9
|
0.01
|
Diuretics
|
59.6
|
64.2
|
0.09
|
|
Obesity
|
9.2
|
8.8
|
-0.01
|
Drugs for acid related disorders
|
38.2
|
45.9
|
0.16
|
|
Osteoarthritis
|
54.6
|
46.7
|
-0.16
|
Drugs for obstructive airway diseases
|
34.5
|
36.8
|
0.05
|
|
Pneumonia
|
10.3
|
6.6
|
-0.13
|
Drugs used in diabetes
|
47.9
|
55.0
|
0.14
|
|
Psoriasis
|
1.9
|
1.6
|
-0.03
|
Immunosuppressants
|
7.0
|
5.7
|
-0.05
|
|
Renal impairment
|
36.2
|
27.4
|
-0.19
|
Lipid modifying agents
|
61.6
|
65.1
|
0.07
|
|
Rheumatoid arthritis
|
8.6
|
7.8
|
-0.03
|
Opioids
|
30.1
|
33.9
|
0.08
|
|
Schizophrenia
|
7.8
|
7.7
|
0.00
|
Psycholeptics
|
53.2
|
55.8
|
0.05
|
|
Ulcerative colitis
|
0.6
|
0.6
|
0.01
|
Psychostimulants, agents used for adhd and nootropics
|
10.9
|
15.7
|
0.14
|
|
Urinary tract infectious disease
|
31.5
|
26.7
|
-0.11
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
1.9
|
1.4
|
-0.04
|
|
25 - 29
|
0.5
|
0.4
|
-0.01
|
Visual system disorder
|
47.6
|
30.1
|
-0.36
|
|
30 - 34
|
0.6
|
0.7
|
0.01
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
0.3
|
1.1
|
0.10
|
Atrial fibrillation
|
33.4
|
26.0
|
-0.16
|
|
40 - 44
|
1.0
|
0.9
|
-0.01
|
Cerebrovascular disease
|
13.3
|
9.7
|
-0.11
|
|
45 - 49
|
2.3
|
2.2
|
-0.01
|
Coronary arteriosclerosis
|
39.6
|
29.7
|
-0.21
|
|
50 - 54
|
2.2
|
2.8
|
0.04
|
Heart disease
|
72.6
|
58.2
|
-0.31
|
|
55 - 59
|
2.9
|
3.2
|
0.02
|
Heart failure
|
29.3
|
24.2
|
-0.12
|
|
60 - 64
|
3.0
|
5.4
|
0.12
|
Ischemic heart disease
|
18.6
|
14.6
|
-0.11
|
|
65 - 69
|
17.0
|
16.2
|
-0.02
|
Peripheral vascular disease
|
40.5
|
27.4
|
-0.28
|
|
70 - 74
|
18.8
|
19.2
|
0.01
|
Pulmonary embolism
|
3.3
|
2.8
|
-0.03
|
|
75 - 79
|
19.1
|
16.4
|
-0.07
|
Venous thrombosis
|
11.0
|
7.1
|
-0.14
|
|
80 - 84
|
15.3
|
14.6
|
-0.02
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.8
|
10.3
|
-0.05
|
Hematologic neoplasm
|
12.2
|
7.8
|
-0.15
|
|
90 - 94
|
2.9
|
3.4
|
0.03
|
Malignant lymphoma
|
4.4
|
3.6
|
-0.04
|
|
95 - 99
|
1.6
|
2.8
|
0.08
|
Malignant neoplasm of anorectum
|
2.6
|
1.7
|
-0.06
|
|
100 - 104
|
0.7
|
0.4
|
-0.04
|
Malignant neoplastic disease
|
39.7
|
26.9
|
-0.27
|
|
Gender: female
|
55.2
|
57.5
|
0.05
|
Malignant tumor of breast
|
5.7
|
3.3
|
-0.12
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
5.5
|
3.4
|
-0.10
|
|
Acute respiratory disease
|
25.5
|
19.5
|
-0.14
|
Malignant tumor of lung
|
4.6
|
3.7
|
-0.05
|
|
Attention deficit hyperactivity disorder
|
0.3
|
0.6
|
0.04
|
Malignant tumor of urinary bladder
|
4.5
|
3.3
|
-0.06
|
|
Chronic liver disease
|
3.5
|
3.0
|
-0.03
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
11.5
|
8.1
|
-0.11
|
Agents acting on the renin-angiotensin system
|
43.1
|
0
|
-1.23
|
|
Crohn’s disease
|
1.0
|
0.7
|
-0.03
|
Antibacterials for systemic use
|
34.6
|
0
|
-1.03
|
|
Dementia
|
14.3
|
11.2
|
-0.09
|
Antidepressants
|
35.6
|
0
|
-1.05
|
|
Depressive disorder
|
11.1
|
8.5
|
-0.09
|
Antiepileptics
|
17.6
|
0
|
-0.65
|
|
Diabetes mellitus
|
66.8
|
48.3
|
-0.38
|
Antiinflammatory and antirheumatic products
|
23.2
|
0
|
-0.78
|
|
Gastroesophageal reflux disease
|
19.6
|
12.9
|
-0.18
|
Antineoplastic agents
|
12.7
|
0
|
-0.54
|
|
Gastrointestinal hemorrhage
|
8.4
|
5.7
|
-0.11
|
Antipsoriatics
|
0.4
|
0
|
-0.09
|
|
Human immunodeficiency virus infection
|
0.4
|
0.5
|
0.01
|
Antithrombotic agents
|
32.9
|
0
|
-0.99
|
|
Hyperlipidemia
|
33.6
|
24.3
|
-0.21
|
Beta blocking agents
|
36.7
|
0
|
-1.08
|
|
Hypertensive disorder
|
4.9
|
4.9
|
0.00
|
Calcium channel blockers
|
27.7
|
0
|
-0.88
|
|
Lesion of liver
|
4.1
|
4.1
|
0.00
|
Diuretics
|
40.2
|
0
|
-1.16
|
|
Obesity
|
7.2
|
5.7
|
-0.06
|
Drugs for acid related disorders
|
25.1
|
0
|
-0.82
|
|
Osteoarthritis
|
55.0
|
39.2
|
-0.32
|
Drugs for obstructive airway diseases
|
21.2
|
0
|
-0.73
|
|
Pneumonia
|
5.9
|
4.6
|
-0.06
|
Drugs used in diabetes
|
30.8
|
0
|
-0.94
|
|
Psoriasis
|
2.5
|
0.6
|
-0.15
|
Immunosuppressants
|
4.6
|
0
|
-0.31
|
|
Renal impairment
|
26.9
|
21.5
|
-0.13
|
Lipid modifying agents
|
42.5
|
0
|
-1.22
|
|
Rheumatoid arthritis
|
9.3
|
5.0
|
-0.17
|
Opioids
|
22.1
|
0
|
-0.75
|
|
Schizophrenia
|
4.6
|
4.4
|
-0.01
|
Psycholeptics
|
32.9
|
0
|
-0.99
|
|
Ulcerative colitis
|
0.7
|
0.2
|
-0.07
|
Psychostimulants, agents used for adhd and nootropics
|
7.3
|
0
|
-0.40
|
|
Urinary tract infectious disease
|
27.6
|
21.0
|
-0.15
|
|
|
|
|
## Drug vs. All ##
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
1.9
|
1.4
|
-0.04
|
|
25 - 29
|
0.5
|
0.4
|
-0.01
|
Visual system disorder
|
47.6
|
30.1
|
-0.36
|
|
30 - 34
|
0.6
|
0.7
|
0.01
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
0.3
|
1.1
|
0.10
|
Atrial fibrillation
|
33.4
|
26.0
|
-0.16
|
|
40 - 44
|
1.0
|
0.9
|
-0.01
|
Cerebrovascular disease
|
13.3
|
9.7
|
-0.11
|
|
45 - 49
|
2.3
|
2.2
|
-0.01
|
Coronary arteriosclerosis
|
39.6
|
29.7
|
-0.21
|
|
50 - 54
|
2.2
|
2.8
|
0.04
|
Heart disease
|
72.6
|
58.2
|
-0.31
|
|
55 - 59
|
2.9
|
3.2
|
0.02
|
Heart failure
|
29.3
|
24.2
|
-0.12
|
|
60 - 64
|
3.0
|
5.4
|
0.12
|
Ischemic heart disease
|
18.6
|
14.6
|
-0.11
|
|
65 - 69
|
17.0
|
16.2
|
-0.02
|
Peripheral vascular disease
|
40.5
|
27.4
|
-0.28
|
|
70 - 74
|
18.8
|
19.2
|
0.01
|
Pulmonary embolism
|
3.3
|
2.8
|
-0.03
|
|
75 - 79
|
19.1
|
16.4
|
-0.07
|
Venous thrombosis
|
11.0
|
7.1
|
-0.14
|
|
80 - 84
|
15.3
|
14.6
|
-0.02
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.8
|
10.3
|
-0.05
|
Hematologic neoplasm
|
12.2
|
7.8
|
-0.15
|
|
90 - 94
|
2.9
|
3.4
|
0.03
|
Malignant lymphoma
|
4.4
|
3.6
|
-0.04
|
|
95 - 99
|
1.6
|
2.8
|
0.08
|
Malignant neoplasm of anorectum
|
2.6
|
1.7
|
-0.06
|
|
100 - 104
|
0.7
|
0.4
|
-0.04
|
Malignant neoplastic disease
|
39.7
|
26.9
|
-0.27
|
|
Gender: female
|
55.2
|
57.5
|
0.05
|
Malignant tumor of breast
|
5.7
|
3.3
|
-0.12
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
5.5
|
3.4
|
-0.10
|
|
Acute respiratory disease
|
25.5
|
19.5
|
-0.14
|
Malignant tumor of lung
|
4.6
|
3.7
|
-0.05
|
|
Attention deficit hyperactivity disorder
|
0.3
|
0.6
|
0.04
|
Malignant tumor of urinary bladder
|
4.5
|
3.3
|
-0.06
|
|
Chronic liver disease
|
3.5
|
3.0
|
-0.03
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
11.5
|
8.1
|
-0.11
|
Agents acting on the renin-angiotensin system
|
43.1
|
0
|
-1.23
|
|
Crohn’s disease
|
1.0
|
0.7
|
-0.03
|
Antibacterials for systemic use
|
34.6
|
0
|
-1.03
|
|
Dementia
|
14.3
|
11.2
|
-0.09
|
Antidepressants
|
35.6
|
0
|
-1.05
|
|
Depressive disorder
|
11.1
|
8.5
|
-0.09
|
Antiepileptics
|
17.6
|
0
|
-0.65
|
|
Diabetes mellitus
|
66.8
|
48.3
|
-0.38
|
Antiinflammatory and antirheumatic products
|
23.2
|
0
|
-0.78
|
|
Gastroesophageal reflux disease
|
19.6
|
12.9
|
-0.18
|
Antineoplastic agents
|
12.7
|
0
|
-0.54
|
|
Gastrointestinal hemorrhage
|
8.4
|
5.7
|
-0.11
|
Antipsoriatics
|
0.4
|
0
|
-0.09
|
|
Human immunodeficiency virus infection
|
0.4
|
0.5
|
0.01
|
Antithrombotic agents
|
32.9
|
0
|
-0.99
|
|
Hyperlipidemia
|
33.6
|
24.3
|
-0.21
|
Beta blocking agents
|
36.7
|
0
|
-1.08
|
|
Hypertensive disorder
|
4.9
|
4.9
|
0.00
|
Calcium channel blockers
|
27.7
|
0
|
-0.88
|
|
Lesion of liver
|
4.1
|
4.1
|
0.00
|
Diuretics
|
40.2
|
0
|
-1.16
|
|
Obesity
|
7.2
|
5.7
|
-0.06
|
Drugs for acid related disorders
|
25.1
|
0
|
-0.82
|
|
Osteoarthritis
|
55.0
|
39.2
|
-0.32
|
Drugs for obstructive airway diseases
|
21.2
|
0
|
-0.73
|
|
Pneumonia
|
5.9
|
4.6
|
-0.06
|
Drugs used in diabetes
|
30.8
|
0
|
-0.94
|
|
Psoriasis
|
2.5
|
0.6
|
-0.15
|
Immunosuppressants
|
4.6
|
0
|
-0.31
|
|
Renal impairment
|
26.9
|
21.5
|
-0.13
|
Lipid modifying agents
|
42.5
|
0
|
-1.22
|
|
Rheumatoid arthritis
|
9.3
|
5.0
|
-0.17
|
Opioids
|
22.1
|
0
|
-0.75
|
|
Schizophrenia
|
4.6
|
4.4
|
-0.01
|
Psycholeptics
|
32.9
|
0
|
-0.99
|
|
Ulcerative colitis
|
0.7
|
0.2
|
-0.07
|
Psychostimulants, agents used for adhd and nootropics
|
7.3
|
0
|
-0.40
|
|
Urinary tract infectious disease
|
27.6
|
21.0
|
-0.15
|
|
|
|
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
beta blocking agents
|
394
|
|
antithrombotic agents
|
352
|
|
nervous system
|
304
|
|
cardiovascular system
|
293
|
|
alimentary tract and metabolism
|
291
|
|
respiratory system
|
249
|
|
blood and blood forming organs
|
239
|
|
antiepileptics
|
224
|
|
sensory organs
|
223
|
|
all other therapeutic products
|
222
|
|
ophthalmologicals
|
222
|
|
lipid modifying agents
|
221
|
|
lipid modifying agents, plain
|
221
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
215
|
|
analgesics
|
214
|
|
diuretics
|
214
|
|
agents acting on the renin-angiotensin system
|
212
|
|
antiinfectives for systemic use
|
203
|
|
stomatological preparations
|
200
|
|
psychoanaleptics
|
199
|
|
antihistamines for systemic use
|
198
|
|
hmg coa reductase inhibitors
|
192
|
|
psycholeptics
|
191
|
|
musculo-skeletal system
|
189
|
|
antibacterials for systemic use
|
185
|
|
cond_180_days
|
n_180_days
|
|
inflammation of specific body systems
|
312
|
|
inflammation of specific body organs
|
305
|
|
pain
|
301
|
|
pain finding at anatomical site
|
301
|
|
heart disease
|
296
|
|
arthropathy
|
290
|
|
vascular disorder
|
266
|
|
diabetes mellitus
|
256
|
|
measurement finding outside reference range
|
256
|
|
soft tissue lesion
|
251
|
|
pain of truncal structure
|
247
|
|
type 2 diabetes mellitus
|
243
|
|
neoplastic disease
|
230
|
|
structural disorder of heart
|
214
|
|
cardiac arrhythmia
|
213
|
|
degenerative disorder of musculoskeletal system
|
197
|
|
osteoarthritis
|
196
|
|
abnormal blood cell count
|
194
|
|
arteriosclerotic vascular disease
|
189
|
|
measurement finding below reference range
|
188
|
|
anemia
|
183
|
|
cytopenia
|
183
|
|
erythropenia
|
183
|
|
hemoglobin level outside reference range
|
183
|
|
hemoglobin low
|
183
|